4 completed, 3 active not recruiting, 3 recruiting, 3 terminated. 9 Phase 1, 5 Phase 2, 1 Not applicable.
Follow Metastatic Castration Resistant Prostate Cancer (mCRPC): new trials by email Literature Review of Metastatic Castration Resistant Prostate Cancer (mCRPC) trials Research Report on Metastatic Castration Resistant Prostate Cancer (mCRPC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabidiol for Pain Relief of Patients With End-stage mCRPC Cannabidiol, Placebo - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Regionshospital Nordjylland | 58 | 2026-06-12 | 2026-09-16 |
| AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) AB-3028 - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Active not recruiting | Arsenal Biosciences, Inc. | 190 | 2026-01-09 | 2026-09-03 |
| Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T 161Tb-PSMA-I&T - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | National Taiwan University Hospital | 12 | 2026-01-01 | 2026-06-02 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC AAA617, ARPI: Abiraterone, ARPI: Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 7 | 2025-09-11 | 2026-10-21 |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland abiraterone, enzalutamide, docetaxel - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Pfizer | 1083 | 2023-02-13 | 2026-01-29 | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer Pidnarulex, Talazoparib - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Suspended | Peter MacCallum Cancer Centre, Australia | 48 | 2022-10-21 | 2023-12-11 |
| The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) WB-MRI - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2 | 2021-02-01 | 2025-04-01 | |
| EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) Radium-223 dichloride (Xofigo, BAY88-8223) - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Bayer | 1180 | 2020-08-03 | 2022-03-31 | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Olaparib, 177Lu-PSMA - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 70 | 2019-07-09 | 2025-05-14 |
| Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer BAY2315497 Injection, Darolutamide(BAY1841788) - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Completed | Bayer | 63 | 2018-12-18 | 2024-11-08 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. NZV930, PDR001, NIR178 - Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Novartis Pharmaceuticals | 127 | 2018-07-18 | 2024-12-13 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Mevrometostat (PF-06821497), Enzalutamide, Itraconazole - Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Pfizer | 453 | 2018-04-17 | 2026-10-15 |
| ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer CPI-1205, Cobicistat, Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 175 | 2017-11-15 | 2025-10-29 |
| Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide Exercise - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Not applicable | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2014-04-01 | 2016-02-11 |
Prostatic Neoplasms (4) · Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lymphoma, Follicular (1) · Marijuana Abuse (1) · Motor Activity (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Genital Diseases (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Prostatic Diseases (4) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2)
enzalutamide (4) · Lutetium-177 (2) · abiraterone (2) · talazoparib (2) · (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (1) · BAY 2315497 (1) · Biological Products (1) · CX 5461 (1) · Cannabidiol (1) · Cobicistat (1) · Docetaxel (1) · Exercise (1) · Goserelin (1) · Itraconazole (1) · Leuprolide (1)
Pfizer (3) · Bayer (2) · Novartis Pharmaceuticals (2) · Peter MacCallum Cancer Centre, Australia (2) · Arsenal Biosciences, Inc. (1) · Constellation Pharmaceuticals (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · National Taiwan University Hospital (1) · Regionshospital Nordjylland (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (9) · Australia (3) · Spain (3) · Finland (2) · Japan (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Denmark (1) · Italy (1) · Russia (1) · Singapore (1)
Shahneen Sandhu (2) · Anthony C Hackney, Ph.D., D.Sc. (1) · Ching-Chu Lu (1) · Giovanni Paganelli, MD (1)
PMID 31831560, PMID 35190653, PMID 40610228, PMID 42221687
2018 (2), 2019 (1), 2023 (1)